TOPROL-XL®, approved by the FDA in 1992, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives the long-term treatment of angina pectoris and the treatment of stable, symptomatic (NYHA class II or III) heart failure of specific origins. rights to TOPROL-XL® (metoprolol succinate) and its Authorized Generic (AG) through an agreement between Melinta and New American Therapeutics Inc. 6, 2022 - Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that it has acquired the U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics
